What is the current size and annual growth rate of the myelofibrosis (mf) market?
The myelofibrosis (MF) market size has grown steadily in recent years. It will grow from $1.50 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to the increasing prevalence of myeloproliferative neoplasms, rising awareness and early diagnosis, growing adoption of JAK inhibitors, expanding access to bone marrow transplants, and increasing regulatory approvals for new therapies.
The myelofibrosis (MF) market size is expected to see steady growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to rising demand for personalized treatment approaches, increasing clinical trials for gene and cell therapies, growing use of combination therapies, expanding healthcare coverage for rare diseases, and increasing investment in hematology care. Major trends in the forecast period include advancements in gene-editing technologies, innovation in fibrosis-targeting drugs, development of next-generation JAK inhibitors, growing interest in immunotherapy for myelofibrosis, and expanding use of artificial intelligence in drug discovery.
Get Your Free Sample of The Global Myelofibrosis (MF) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp
Which major factors have contributed to the expansion of the myelofibrosis (mf) market?
Growing demand for targeted therapies is expected to propel the growth of the myelofibrosis (MF) market going forward. Targeted therapies are a medical approach that tailors treatments and healthcare decisions based on individual genetic, environmental, and lifestyle factors. The increasing demand for targeted therapies is driven by advancements in genomics, biotechnology, and data analytics, enabling more precise, effective, and individualized treatments. Myelofibrosis (MF) provides a critical framework for the development of targeted therapies by identifying key molecular pathways, such as JAK-STAT signaling, which enable the design of precision treatments like JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) to manage symptoms and slow disease progression. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based government organization, the total number of therapies across all stages of clinical pipeline development has grown, with Phase I therapies experiencing the most significant increase—rising by 11%—the highest growth rate since Q4 2022. Therefore, growing demand for targeted therapies is driving the growth of the myelofibrosis (MF) market.
How is the myelofibrosis (mf) market segmented?
The myelofibrosis (MF) market covered in this report is segmented –
1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib
2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide
3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea
4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report
Who are the top competitors in the myelofibrosis (mf) market?
Major companies operating in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation
Which key trends are expected to influence the myelofibrosis (mf) market in the coming years?
Major companies operating in the myelofibrosis (MF) market are focusing on the expansion of targeted therapies, such as JAK1/JAK2 and ACVR1 inhibitors, to enhance treatment efficacy, address disease progression, and improve patient outcomes in myelofibrosis (MF). JAK1/JAK2 inhibitors target the Janus kinase pathway to reduce inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors block activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease progression. For instance, in September 2023, GSK plc, a UK-based pharmaceutical company, has received US Food and Drug Administration (FDA) approval for Ojjaara (momelotinib), indicated for the treatment of intermediate- or high-risk myelofibrosis. Its dual mechanism of action, targeting both JAK1/JAK2 and ACVR1, helps regulate inflammatory pathways while also improving hemoglobin levels, reducing the need for transfusions. This approval not only expands treatment options but also sets a new standard in MF management for patients struggling with anemia, a major unmet need in the disease landscape.
Which regional trends are influencing the myelofibrosis (mf) market, and which area dominates the industry?
North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (MF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Myelofibrosis (MF) Market Report 2025 Offer?
The myelofibrosis (mf) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Myelofibrosis (MF) refers to a rare bone marrow disorder characterized by excessive scar tissue formation, which disrupts normal blood cell production. This condition can lead to anemia, an enlarged spleen, and symptoms such as fatigue, night sweats, and bone pain.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21226
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
